Prestige Biopharma Seeks Collaboration Opportunities at BIO USA
Pursuing Partnerships in Antibody Drugs and Biosimilars
Prestige Biopharma announced on the 16th that it will participate in "BIO USA 2026," which will be held in San Diego, USA from June 22 to 25 (local time), to expand business development with global pharmaceutical and biotechnology companies.
At this event, the company plans to accelerate its two-track strategy, focusing on global antibody drug partnering and expanding biosimilar commercialization. In the antibody drug segment, Prestige Biopharma will initiate joint development and technology transfer discussions for PBP1510 and PBP1710. In the biosimilar segment, the focus will be on advancing the North American entry and global commercialization of the Avastin biosimilar "HD204" (brand name: Vasforada), and on selecting a North American partner for the Herceptin biosimilar "HD201" (brand name: Tuzneu).
Prestige Biopharma Group plans to discuss joint development and commercialization strategies for its follow-up pipeline with global pharmaceutical and biotechnology companies, based on its integrated value chain that connects development, production, and commercialization. The company will also showcase its technology for subcutaneous (SC) formulation conversion of antibody medicines, as well as its AI-based research and development and biomanufacturing capabilities.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In addition, Prestige Biopharma will share its AI application capabilities in drug target discovery, antibody optimization, bioprocessing, and quality prediction, as well as the current status of next-generation antibody delivery platform research and development. The company will also explore collaboration opportunities with related companies.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.